Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease

SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease (SNU PREVENT)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this observational study is to investigate characteristics of individuals at high risk for developing Inflammatory Bowel Disease (IBD) in order to identify risk factors associated with its incidence. The main question it aims to answer is: What are the risk factors for developing Inflammatory Bowel Disease? Researchers will compare groups at high risk for IBD to healthy populations and to patients already diagnosed with IBD. Participants will * undergo assessments of general demographic and clinical characteristics. * be monitored for symptoms using questionnaires administered at regular intervals. * have blood tests and stool examinations performed. In cases where participants undergo colonoscopy for routine clinical indications, gut biopsies will also be performed.

Who May Be Eligible (Plain English)

Who May Qualify: - first-degree relatives of Inflammatory Bowel Disease patients - patients who are diagnosed with autoimmune conditions (where your immune system attacks your own body)s - patients with functional gastrointestinal disorders who are ASCA-positive Who Should NOT Join This Trial: - Patients with symptoms such as a 10% weight loss within 3 months, abdominal pain, hematochezia, or diarrhea will undergo colonoscopy, and those diagnosed with Inflammatory Bowel Disease will be excluded. - Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * first-degree relatives of Inflammatory Bowel Disease patients * patients who are diagnosed with autoimmune diseases * patients with functional gastrointestinal disorders who are ASCA-positive Exclusion Criteria: * Patients with symptoms such as a 10% weight loss within 3 months, abdominal pain, hematochezia, or diarrhea will undergo colonoscopy, and those diagnosed with Inflammatory Bowel Disease will be excluded. * Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer.

Locations (1)

Seoul National University Hospital
Seoul, South Korea